CNSP:NSD-CNS Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.74

Change

-0.06 (-2.14)%

Market Cap

USD 0.07B

Volume

0.18M

Average Target Price

USD 10.00 (+264.96%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas. Address: 2100 West Loop South, Houston, TX, United States, 77027

Company Website : http://www.cnspharma.com

Address : 2100 West Loop South, Houston, TX, United States, 77027

Employees : 3

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 4.46

Short Ratio : 0.14

52 Week Low : 1.26

Shorted Shares : 520,601

200 Day Moving Average : 2.17

Shorted Shares Previous Month : 65,975

50 Day Moving Average : 2.62

Shares Held By Insiders : 435.87%

Short Percentage : 2.00%

Shares Held by Institutions : 0.47%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.59 (-6.73%)

 USD62.28B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.68 (+0.80%)

 USD54.69B 20.45 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.19 (-1.77%)

 USD49.61B 15.17 11.55
ALXN Alexion Pharmaceuticals, Inc

-1.60 (-1.05%)

 USD33.27B 55.63 33.22
RPRX Royalty Pharma plc

-1.08 (-2.25%)

 USD29.16B 22.60 14.17
BGNE BeiGene, Ltd

-12.93 (-4.05%)

 USD29.03B N/A N/A
SGEN Seagen Inc

+1.16 (+0.76%)

 USD27.64B 45.27 37.70
BNTX BioNTech SE

-5.23 (-4.75%)

 USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.29 (-3.67%)

 USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing CNSP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.93% 84% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.93% 84% B 88% B+
Trailing 12 Months  
Capital Gain -29.92% 15% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.92% 15% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.18% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.18% 24% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 19.75% 94% A 70% C-
Risk Adjusted Return -51.53% 16% F 11% F
Market Capitalization 0.07B 10% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 95% A 98% A+
Price/Book Ratio 5.59 52% F 33% F
Price / Cash Flow Ratio -9.47 50% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -87.78% 34% F 13% F
Return on Invested Capital -86.00% 31% F 11% F
Return on Assets -49.73% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.14 90% A- 89% B+
Short Percent 3.41% 72% C- 49% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.